Chugai Pharmaceutical (OTCMKTS:CHGCY) Shares Gap Down – Here’s What Happened

Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (OTCMKTS:CHGCY)’s share price gapped down before the market opened on Tuesday. The stock had previously closed at $21.79, but opened at $20.37. Chugai Pharmaceutical shares last traded at $21.30, with a volume of 32,124 shares trading hands.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on CHGCY. Nomura raised shares of Chugai Pharmaceutical to a “hold” rating in a research note on Tuesday, September 1st. UBS Group downgraded shares of Chugai Pharmaceutical from a “strong-buy” rating to a “hold” rating in a research report on Thursday, August 6th. One research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat.com, Chugai Pharmaceutical presently has a consensus rating of “Moderate Buy”.

Chugai Pharmaceutical Stock Up 0.2%

The firm has a market cap of $71.85 billion, a PE ratio of 23.73 and a beta of 0.60. The stock has a 50 day moving average price of $20.75 and a two-hundred day moving average price of $24.66.

Chugai Pharmaceutical (OTCMKTS:CHGCY) last announced its quarterly earnings data on Tuesday, October 27th. The company reported $0.27 EPS for the quarter. Chugai Pharmaceutical had a net margin of 35.09% and a return on equity of 23.76%. As a group, equities analysts anticipate that Chugai Pharmaceutical Co., Ltd. Unsponsored ADR will post 0.96 earnings per share for the current year.

Chugai Pharmaceutical Company Profile

Chugai Pharmaceutical Co, Ltd. is a Japan-based research-driven pharmaceutical company that develops, manufactures and markets prescription medicines. Its operations focus on addressing unmet medical needs through biotechnology, antibody engineering and other advanced drug-discovery technologies.

The company’s principal therapeutic areas include oncology, hematology, immunology, rheumatology, neuroscience, renal diseases and bone disorders. Its portfolio includes medicines such as Actemra (tocilizumab), used in several inflammatory conditions; Hemlibra (emicizumab), a treatment for hemophilia A; Alecensa (alectinib), an oncology medicine; and Enspryng (satralizumab), used for neuromyelitis optica spectrum disorder.

Founded in Japan in 1925, Chugai is headquartered in Tokyo and primarily serves the Japanese market while also commercializing products internationally through its strategic relationship with Roche.